HIGH RISK MYELODYSPLASTIC SYNDROME
Clinical trials for HIGH RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HIGH RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for HIGH RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a 'Universal' cancer target outsmart resistant blood cancers?
Disease control Not yet recruitingThis early-phase trial is testing an experimental drug called VTRU200 in people with certain blood cancers that have returned or not responded to standard treatments, including acute myeloid leukemia, high-risk myelodysplastic syndromes, and diffuse large B-cell lymphoma after CA…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Vitruviae • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new oral drug take on hard-to-treat leukaemia?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called AMX-883, taken by mouth, for people with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. The study will first test AMX-883 alone, th…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Amphista Therapeutics Ltd • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Weekly pill cocktail aims to tame resistant blood cancers
Disease control Not yet recruitingThis phase 2 trial tests whether a once-weekly oral combination of decitabine-cedazuridine and venetoclax is safer and as effective as standard therapy for people with relapsed or refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, or high-risk myeloproliferati…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for tough leukemia? drug duo targets TP53 mutations
Disease control Not yet recruitingThis early-phase study tests a new drug (ATRN-119) combined with a standard chemotherapy (decitabine) in 27 adults with acute myeloid leukemia or high-risk myelodysplastic syndrome that has a TP53 gene change. The main goals are to find a safe dose and see if the combo can shrink…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC